EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response

Ruby Pandher, Chengyuan Xue iD, Laura D Gamble iD, Giorgio Milazzo iD, Simone Di Giacomo iD, Jayne Murray, Leanna Cheung iD, Francesca Ferrucci, Marta Palombo, Stefania Purgato, Catherine A Burkhart iD, Natalia Fedtsova und 14 weitere

Proceedings of the National Academy of Sciences · 10.06.2025 · 122 (23)

DOI: 10.1073/pnas.2420011122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 02.06.2025. Verfasst von Ruby Pandher und 25 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Iron Chelating Agents, E2F3 Transcription Factor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federal Government | DHAC | National Health and Medical Research Council (NHMRC), NCI NIH HHS, Fondazione AIRC per la ricerca sul cancro ETS (AIRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite Myc oncoproteins being major causal factors in human cancer, they remain “undruggable.” The MYCN oncogene is one of the most powerful prognostic markers for the childhood cancer neuroblastoma and represents an important target for developing novel therapeutics. Here, we report the finding and characterization of M606, a selective small molecule inhibitor of MYCN, which was identified by screening a diverse chemical library. M606 reduced MYCN protein levels in neuroblastoma cell lines and upregulated hypoxia-inducible factor 1 alpha (HIF1A). Using siRNA-mediated knockdown of MYCN , c-Myc , or HIF1A in HepG2 and BE(2)-C cells followed by M606 treatment, we demonstrated that Myc downregulation and HIF1A upregulation were two independent effects of M606 treatment. M606 selectively targeted neuroblastoma cell lines expressing higher levels of MYCN protein and delayed neuroblastoma development in the TH-MYCN transgenic mouse model. Metabolomic analysis showed that M606 modulated glucose metabolism, consistent with a hypoxic response and iron deprivation. Biochemical characterization of M606 not only confirmed its iron-chelating properties but also revealed its ability to downregulate MYCN promoter activity, which could be rescued by the addition of iron. Luciferase assays identified the minimal MYCN promoter region required for the M606 response, which contained overlapping E2F transcription factor binding sites. Further evaluation defined a key role for E2F3 in the M606-mediated response. The finding of a potent cell-permeable iron chelator that can chelate iron to directly downregulate MYCN transcription via an E2F3-mediated response represents a potentially valuable therapeutic approach in the treatment of cancers overexpressing Myc oncoproteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaN-Myc Proto-Oncogene ProteinIron Chelating AgentsE2F3 Transcription FactorHumansAnimalsMiceCell Line, TumorHypoxia-Inducible Factor 1, alpha SubunitGene Expression Regulation, NeoplasticMice, TransgenicIron

Stichwörter der Autor:innen

E2FMYCN oncogeneiron chelationneuroblastoma

Substanzen

N-Myc Proto-Oncogene ProteinMYCN protein, humanIron Chelating AgentsE2F3 Transcription FactorHypoxia-Inducible Factor 1, alpha SubunitE2F3 protein, humanHIF1A protein, humanIron

Autor:innen und Institutionen

  • Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.
  • Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.
  • Buffalo BioLabs, Limited Liability Company, Buffalo, NY 14203.
  • Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203.
  • Genome Protection, Inc., Buffalo, NY 14203.
  • Attagene Inc, NC 27560.

ORCID-Profile: Chengyuan Xue, Laura D Gamble, Giorgio Milazzo, Simone Di Giacomo, Leanna Cheung, Catherine A Burkhart, Anatoli S Gleiberman, Sergei S Makarov, Thomas J Telfer, Rachel Codd, Glenn M Marshall, David A Scott, Andrei L Osterman, Andrei V Gudkov, Giovanni Perini, Michelle Haber, Murray D Norris

Förderung

  • Federal Government | DHAC | National Health and Medical Research Council (NHMRC)
  • NCI NIH HHS
  • Fondazione AIRC per la ricerca sul cancro ETS (AIRC)
  • Neuroblastoma Australia
  • Cancer Institute NSW (Cancer Institute New South Wales)
  • Tour de Cure (TDC)

Zitieren

APA

Pandher, R., Xue, C., Gamble, L. D., Milazzo, G., Di Giacomo, S., Murray, J., Cheung, L., Ferrucci, F., Palombo, M., Purgato, S., Burkhart, C. A., Fedtsova, N., Gleiberman, A. S., Purmal, A. A., Korotchkina, L., Nikiforov, M. A., Makarov, S. S., Telfer, T. J., Codd, R., …, & Norris, M. D. (2025). The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response. Proceedings of the National Academy of Sciences, 122(23). https://doi.org/10.1073/pnas.2420011122

Vancouver

Pandher R, Xue C, Gamble LD, Milazzo G, Di Giacomo S, Murray J, et al. The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response. Proceedings of the National Academy of Sciences. 2025;122(23). doi:10.1073/pnas.2420011122

BibTeX
@article{Pandher2025,
  author = {Pandher, Ruby and Xue, Chengyuan and Gamble, Laura D and Milazzo, Giorgio and Di Giacomo, Simone and Murray, Jayne and Cheung, Leanna and Ferrucci, Francesca and Palombo, Marta and Purgato, Stefania and Burkhart, Catherine A and Fedtsova, Natalia and Gleiberman, Anatoli S and Purmal, Andrei A and Korotchkina, Lioubov and Nikiforov, Mikhail A and Makarov, Sergei S and Telfer, Thomas J and Codd, Rachel and Marshall, Glenn M and Scott, David A and Osterman, Andrei L and Gudkov, Andrei V and Perini, Giovanni and Haber, Michelle and Norris, Murray D},
  title = {The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {23},
  doi = {10.1073/pnas.2420011122}
}
Kostenlos starten →